ICON plc
, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of a
new medical imaging solution
tailored to the unique requirements of early phase trials.
This new solution incorporates streamlined processes and procedures to maximize the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research. Enhanced decision making is then enabled by
MIRA™
, ICON’s image management system, which standardizes data from all imaging formats and allows for centralized analysis and interpretation of data. Driving this innovation is a team of scientific and regulatory experts with deep imaging and early-phase experience to help sponsors make critical decisions about their compounds faster.
“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” commented
Ted Gastineau
, President, ICON Medical Imaging. “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”
ICON Medical Imaging’s early phase group will be led by Dr. James Conklin, Senior Vice President, Medical and Scientific Affairs and Dr. Valerie Treyer, Director, Medical and Scientific Affairs, who together bring over 45 years of experience in the management of medical image data used in clinical trials. The group will work closely with
ICON Development Solutions
which provides a full range of early-phase services, including
clinical pharmacology
,
bioanalytical
,
PK/PD modelling and simulation
, and
Clinical Pharmacodynamic Models
for early indications of drug efficacy.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.